NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Celcuity Inc. Common Stock (CELC) Stock Analysis

Celcuity Inc. Common Stock (CELC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CELC

$95.70

−$0.73 (−0.76%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CELC with… →

CELC Key Statistics

As of Sep 4, 2026
Trading
Open
$95.83
Previous Close
$96.43
Day's Range
94.55–97.25
52-Week Range
44.42–151.02
Volume
515.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.20
Valuation
Market Cap
$4.68B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.27
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$177.04M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
48.93M
1-Year Return
+75.69%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
1.28M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CELC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−4.05%
2025+661.96%
2024−10.16%
2023+4.00%
2022+6.22%
2021+44.00%
2020−13.91%
2019−55.65%
2018+26.60%
2017 (partial year)+32.61%

As of September 4, 2026.

CELC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$177.04M—
2024$0.00−$111.78M—
2023$0.00−$63.78M—
2022$0.00−$40.37M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$172.19M−$177.04M—
2024$0.00—−$113.27M−$111.78M—
2023$0.00—−$66.23M−$63.78M—
2022$0.00—−$39.39M−$40.37M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CELC Valuation vs Biotechnology Median

Median of 656 stocks
MetricCELCBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Celcuity Inc. Common Stock (CELC) carries a market capitalisation of $4.68B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 155 employees.

CELC last closed at $95.70 on September 4, 2026. That is −$0.73 (−0.76%) against the previous close. Over the past 52 weeks the price has ranged from $44.42 to $151.02. The latest close sits 115.44% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $177.04M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −4.27.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.2. Annualized volatility over the trailing 9 years is 90.94%. The trailing one-year price return is +75.69%. Across 5 years the annualized return works out at +34.80%.

Growth & Income

The record shows no dividend for CELC.

So far in 2026 the price is −4.05%. The strongest complete calendar year on file is 2025 at +661.96%; the weakest is 2019 at −55.65%. Of the 8 complete calendar years on file, 5 finished higher.

Peer Comparison

Celcuity Inc. Common Stock (CELC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Celcuity Inc. Common Stock CELC $4.68B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Celcuity Inc. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Celcuity Inc. Common Stock

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

Visit website →